DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4fj74t/pharmaceutical) has announced the addition of the "Pharmaceutical Industry in Ghana and Nigeria" report to their offering.
The pharmaceutical industry in Ghana and Nigeria is forecast to represent a combined business opportunity of over $3 billion by 2018, propelled by a convergence of changing economic profiles, increased healthcare spending and investment, and increasing incidence of chronic diseases. Market segmentation is done based on products (OTC, generic, and branded) as well as therapeutic areas (anti-infectives, cardiovascular, diabetes, oncology, respiratory, and CNS).
This study provides a detailed analysis that includes market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the pharmaceutical industry in Ghana and Nigeria.
Key Questions This Study Will Answer
- Is the pharmaceutical industry in Ghana and Nigeria growing, how long will it continue to grow, and at what rate?
- What are the fastest growing product and therapeutic segments of the pharmaceutical industry in Ghana & Nigeria?
- What opportunities exist in the Ghanaian and Nigerian pharmaceutical industry?
- What are the key drivers and restraints affecting the growth of the pharmaceutical industry in Ghana and Nigeria?
- What are the key challenges the Ghanaian and Nigerian pharmaceutical will likely face in the near and long-term future?
In what ways is the pharmaceutical industry in Ghana and Nigeria
likely to change to meet industry challenges?
- Although the oncology therapeutic segment accounted for the smallest revenue share in 2013, it is expected to be the fastest growing segment during the forecast period, given the increasing awareness about cancer in Ghana and Nigeria.
- The cardiovascular and diabetes therapeutic segments are also projected to witness high growth rates during the forecast period as a result of increasing adoption of western lifestyle, driving the demand for consumption of chronic drugs.
- The continuous burden of anti-infectives, including malaria, tuberculosis (TB), and HIV/AIDS in West Africa is expected to be the major growth driver for this industry.
- The increased prevalence of non-communicable diseases (NCDs) such as hypertension, diabetes, and cancer in Ghana and Nigeria is expected to have a high impact on the growth of the total pharmaceutical industry as the demand for chronic prescription therapy for these diseases rises.
- The judicious efforts of the Food and Drugs Board (FDB) (Ghana) and National Agency for Food (NAFDAC) (Nigeria) to control parallel trading and imports of counterfeit drugs are expected to contribute to the growth of the legitimate pharmaceutical industry in Ghana and Nigeria.
- Furthermore, the governments are also encouraging the local production of essential medicines to improve capacity utilisation and reduce imports.
Key Topics Covered:
1. Executive Summary
2. Market Overview
3. Competitive Playbook
4. Drivers and Restraints - Total Pharmaceutical Industry in Ghana and Nigeria
5. Forecasts and Trends - Total Pharmaceutical Industry in Ghana and Nigeria
6. Ghanaian Pharmaceutical Industry Overview
7. Ghanaian Pharmaceutical Industry - Forecasts and Trends
8. Ghanaian Pharmaceutical Industry - Demand Analysis
9. Ghanaian Pharmaceutical Industry - Competitive Landscape
10. Nigerian Pharmaceutical Industry Overview
11. Nigerian Pharmaceutical Industry - Forecasts and Trends
12. Nigerian Pharmaceutical Industry - Demand Analysis
13. Nigerian Pharmaceutical Industry - Competitive Landscape
14. Key Companies to Watch
15. The Last Word
- Aryton Drugs Manufacturing Company
- Danadams Pharmaceuticals
- Dr. Reddy's
- Emzor Pharmaceutical Industries
- Ernest Chemist
- Evans Medical
- Fidson Healthcare
- Kama Group
- LUEX Healthcare
- May & Baker Nigeria
- Nigeria German Chemicals
- Phytoriker (GIHOC)
- Sanofi Aventis
For more information visit http://www.researchandmarkets.com/research/4fj74t/pharmaceutical